Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

4D Molecular Therapeutics, Inc. Announces Rare Disease Ophthalmology Product Candidate Portfolio Update

06/25/2021 | 04:01pm EDT

4D Molecular Therapeutics announced an update on their rare disease ophthalmology product candidate portfolio including Phase 1 dose escalation clinical trial safety and tolerability data with 4D-110 for choroideremia and 4D-125 for X-linked retinitis pigmentosa (XLRP) (n=12 patients total), and that the company received a notice of termination of the Collaboration and License Agreement by 4D-110 licensee Roche resulting in full rights to 4D-110 reverting to 4DMT. Initial Phase 1 Dose Escalation Safety and Tolerability Data Summary: 4D-110 for choroideremia and 4D-125 for X-linked retinitis pigmentosa Clinical trial designs and enrollment Both clinical trials employed standard “3+3” dose-escalation designed to assess the safety, tolerability and biologic activity of a single intravitreal injection of either 4D-110 or 4D-125 at two dose levels (3E11 or 1E12 vg/eye). A total of twelve patients were enrolled across dose escalation cohorts, including six who received 4D-110 (three at each dose level) and six who received 4D-125 (three at each dose level). Patients received a standard immunosuppression regimen with taper; adjustments were determined by investigators. The results described are based on data cut-offs as of April 12, 2021 for 4D-110 and April 27, 2021 for 4D-125.


ę S&P Capital IQ 2021
All news about 4D MOLECULAR THERAPEUTICS, INC.
08/124D MOLECULAR THERAPEUTICS : Reports Financial Results for the Second Quarter of ..
PU
08/124D MOLECULAR THERAPEUTICS : Management's Discussion and Analysis of Financial Co..
AQ
08/124D MOLECULAR THERAPEUTICS INC. : Results of Operations and Financial Condition, ..
AQ
08/124D MOLECULAR THERAPEUTICS : Earnings Flash (FDMT) 4D MOLECULAR THERAPEUTICS Repo..
MT
08/124D MOLECULAR THERAPEUTICS : Reports Financial Results for the Second Quarter of ..
AQ
08/124D Molecular Therapeutics, Inc. Announces Unaudited Earnings Results for the ..
CI
08/124D Molecular Therapeutics, Inc. Appoints Nadine Greiner as Chief Human Resour..
CI
06/254D MOLECULAR THERAPEUTICS INC. : Termination of a Material Definitive Agreement,..
AQ
06/254D Molecular Therapeutics, Inc. Announces Rare Disease Ophthalmology Product ..
CI
06/254D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 3000E Growth Index
CI
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 16,9 M - -
Net income 2021 -71,0 M - -
Net cash 2021 196 M - -
P/E ratio 2021 -13,3x
Yield 2021 -
Capitalization 939 M 939 M -
EV / Sales 2021 43,9x
EV / Sales 2022 155x
Nbr of Employees 104
Free-Float 76,9%
Chart 4D MOLECULAR THERAPEUTICS, INC.
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | FDMT | US35104E1001 | MarketScreener
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 34,80 $
Average target price 50,00 $
Spread / Average Target 43,7%
EPS Revisions
Managers and Directors
David H. Kirn President, Chief Executive Officer & Director
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Melissa Kotterman Vice President-Discovery & Engineering
Fred Kamal Chief Operating & Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
4D MOLECULAR THERAPEUTICS, INC.-16.04%939
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420